NCT06639685

Brief Summary

To explore the value of MR Fingerprinting-generated quantitative maps combined with ASL renal perfusion imaging in the assessment of renal impairment in chronic kidney disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2024

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2024

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

October 10, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 15, 2024

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

October 15, 2024

Status Verified

October 1, 2024

Enrollment Period

12 months

First QC Date

October 10, 2024

Last Update Submit

October 10, 2024

Conditions

Chronic Kidney Disease(CKD)MRI

Keywords

Chronic Kidney DiseaseMR FingerprintingASL

Outcome Measures

Primary Outcomes (1)

  • T1 and T2 value

    T1 and T2 value generated by MR Fingerprinting

    3 months

Study Arms (1)

CKD

Chronic Kidney Disease

Diagnostic Test: MRI

Interventions

MRIDIAGNOSTIC_TEST

MR Fingerprinting and ASL

CKD

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients who were diagnosed with chronic kidney disease by renal biopsy

You may qualify if:

  • Patients diagnosed with chronic kidney disease (CKD) by renal biopsy

You may not qualify if:

  • Patients with serious underlying diseases
  • Patients with MRI incompatible metal implants and contraindications such as claustrophobia
  • Patients with imperfect clinical data and pathological data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The First Affiliated Hospital with Nanjing Medical University

Nanjing, Jiangsu, China

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Yu dong Zhang, MD,PHD

CONTACT

+86 158-0515-1704zhangyd3895@njmu.edu.cn

Shuai Shan

CONTACT

+86 198-5092-2832njmu_ss@stu.njmu.edu.cn

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 10, 2024

First Posted

October 15, 2024

Study Start

October 1, 2024

Primary Completion

September 30, 2025

Study Completion

December 31, 2025

Last Updated

October 15, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)